Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context

Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context

Summary: Background: Anlotinib is a novel highly potent multitargeted tyrosine kinase inhibitor. However, the safety, recommended dosage, pharmacokinetics (PK) characteristics, and efficacy of anlotinib in paediatric patients have not been fully studied. We aimed to evaluate the safety, PK, and fea...

Full description

Saved in:
Bibliographic Details
Main Authors: Suying Lu, Yi Que, Dongyang Liu, Feifei Sun, Xueting Yao, Liting Deng, Jing Zhan, Junting Huang, Ruiqing Cai, Xin Wang, Shixing Zhu, Zijun Zhen, Jia Zhu, Juan Wang, Yizhuo Zhang
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:EClinicalMedicine
Subjects:
Anlotinib
Paediatric
Sarcoma
High risk
Recurrent
Refractory
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025001907
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025001907

Similar Items